{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:14:24Z","timestamp":1768270464073,"version":"3.49.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jval.2021.12.016","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:18:06Z","timestamp":1648167486000},"page":"1235-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review"],"prefix":"10.1016","volume":"25","author":[{"given":"Hailey","family":"Saunders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba\u2019","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond","family":"Loong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda M.","family":"Ashoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesmin","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazia","family":"Darvesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silkan K.","family":"Bains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Plett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srushhti","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea C.","family":"Tricco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanrudee","family":"Isaranuwatchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jval.2021.12.016_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","article-title":"Insulin analogues in type 1 diabetes mellitus: getting better all the time","volume":"13","author":"Mathieu","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14740338.2021.1856813","article-title":"Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions","volume":"20","author":"Lefever","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jval.2021.12.016_bib4","series-title":"Endotext","article-title":"Insulin - pharmacology, therapeutic regimens, and principles of intensive insulin therapy","author":"Donner","year":"2019"},{"key":"10.1016\/j.jval.2021.12.016_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2021.12.016_bib9","doi-asserted-by":"crossref","first-page":"g5459","DOI":"10.1136\/bmj.g5459","article-title":"Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis","volume":"349","author":"Tricco","year":"2014","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jval.2021.12.016_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin access and affordability working group: conclusions and recommendations [published correction appears in Diabetes Care. 2018;41(8):1831]","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1932296815605337","article-title":"Biosimilar insulin and costs: what can we expect?","volume":"10","author":"Heinemann","year":"2015","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/cd16-0072","article-title":"How similar are biosimilars? What do clinicians need to know about biosimilar and follow-on insulins?","volume":"35","author":"Triplitt","year":"2017","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.1016\/j.jval.2021.12.016_bib13","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s11606-021-06642-7","article-title":"Comparative efficacy and safety of ultra-long-acting, long-acting, intermediate-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review and network meta-analysis","volume":"36","author":"Tricco","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"24","key":"10.1016\/j.jval.2021.12.016_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/jama.1995.03530240045039","article-title":"The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care","volume":"274","author":"Bero","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","article-title":"Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report","volume":"24","author":"Mandrik","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2021.12.016_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jval.2021.12.016_bib18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","article-title":"An evidence-based practice guideline for the peer review of electronic search strategies","volume":"62","author":"Sampson","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jval.2021.12.016_bib19","author":"Synthesi"},{"key":"10.1016\/j.jval.2021.12.016_bib20","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy J Res Debate Pract"},{"issue":"25","key":"10.1016\/j.jval.2021.12.016_bib22","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jval.2021.12.016_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1185\/030079904X5661","article-title":"Cost-effectiveness of detemir-based basal\/bolus therapy versus NPH-based basal\/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02850126","article-title":"Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH","volume":"23","author":"Valentine","year":"2006","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1185\/030079907X182194","article-title":"An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK","volume":"23","author":"Palmer","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2021.12.016_bib26","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1185\/030079907X167561","article-title":"Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK","volume":"23","author":"McEwan","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00019053-200725030-00007","article-title":"Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada","volume":"25","author":"Grima","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1503\/cmaj.081180","article-title":"Cost-effectiveness of insulin analogues for diabetes mellitus","volume":"180","author":"Cameron","year":"2009","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.jval.2021.12.016_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1185\/03007990902869169","article-title":"Cost-effectiveness of insulin detemir compared to NPH Insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis","volume":"25","author":"Tunis","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib30","first-page":"114","article-title":"Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries","volume":"12","author":"Gschwend","year":"2009","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1403494810379290","article-title":"Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden","volume":"39","author":"Valentine","year":"2011","journal-title":"Scand J Public Health"},{"issue":"suppl 2","key":"10.1016\/j.jval.2021.12.016_bib32","first-page":"14","article-title":"Health economic evaluation of insulin glargine vs NPH Insulin in intensified conventional therapy for type 1 diabetes in Germany","volume":"15","author":"Pfohl","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-5491.2011.03461.x","article-title":"Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with insulin detemir or NPH Insulin in Denmark, Sweden, Finland and The Netherlands","volume":"29","author":"Valentine","year":"2012","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.jval.2021.12.016_bib34","first-page":"1442","article-title":"Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden","volume":"16","author":"Ericsson","year":"2013","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13300-015-0143-x","article-title":"Cost-effectiveness analysis of insulin detemir compared to neutral protamine Hagedorn (NPH) in patients with type 1 and type 2 diabetes mellitus in Spain","volume":"6","author":"Morales","year":"2015","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib36","first-page":"56","article-title":"Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK","volume":"18","author":"Evans","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"10","key":"10.1016\/j.jval.2021.12.016_bib37","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2016.1205006","article-title":"Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia","volume":"32","author":"Pedersen-Bjergaard","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03007995.2016.1277194","article-title":"Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data","volume":"33","author":"Landstedt-Hallin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.jval.2021.12.016_bib39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jval.2017.05.021","article-title":"Basal insulin regimens for adults with type 1 diabetes mellitus: a cost-utility analysis","volume":"20","author":"Dawoud","year":"2017","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2021.12.016_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14737167.2017.1345628","volume":"17","author":"Mezquita-Raya","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13300-017-0236-9","article-title":"Cost-effectiveness of insulin Degludec versus insulin glargine in adults with Type 1 and type 2 diabetes mellitus","volume":"8","author":"Evans","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib42","first-page":"213","article-title":"A\u00a0short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark","volume":"20","author":"Pollock","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s13300-018-0426-0","article-title":"Cost-effectiveness of insulin Degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia","volume":"9","author":"Lali\u0107","year":"2018","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.jval.2021.12.016_bib44","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s13300-018-0478-1","article-title":"Cost-Effectiveness of insulin Degludec vs. insulin glargine U100 in type 1 and type 2 diabetes mellitus in a UK Setting","volume":"9","author":"Evans","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jval.2021.12.016_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/DMSO.S156739","article-title":"Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach","volume":"11","author":"Pollock","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12902-019-0460-6","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria","volume":"19","author":"Russel-Szymczyk","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib47","first-page":"271","article-title":"Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy","volume":"23","author":"Haldrup","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"11","key":"10.1016\/j.jval.2021.12.016_bib48","first-page":"1311","article-title":"Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective","volume":"23","author":"Jendle","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"15","key":"10.1016\/j.jval.2021.12.016_bib49","first-page":"1250","article-title":"Sundheds\u00f8konomiske konsekvenser af insulinanaloger til behandling af type 1-diabetes i Danmark","volume":"170","author":"Palmer","year":"2008","journal-title":"Ugeskr L\u00e6ger"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1503\/cmaj.081041","article-title":"Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis","volume":"180","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2021.12.016_bib51","series-title":"Type 1 Diabetes in Adults: Diagnosis and Management","year":"2015"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","article-title":"Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials","volume":"5","author":"Vora","year":"2014","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.jval.2021.12.016_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of insulin Degludec vs insulin glargine U100 on hypoglycemia in patients with Type 1 diabetes: the SWITCH 1 randomized clinical trial","volume":"318","author":"Lane","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jval.2021.12.016_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1464-5491.2004.01323.x","article-title":"Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin","volume":"21","author":"Porcellati","year":"2004","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1464-5491.2007.02407.x","article-title":"Long-term efficacy and safety of insulin detemir compared to Neutral protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial","volume":"25","author":"Bartley","year":"2008","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.jval.2021.12.016_bib57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/dom.13149","article-title":"A\u00a0European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes","volume":"20","author":"Siegmund","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.jval.2021.12.016_bib58","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1210\/jc.2019-01021","article-title":"Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study","volume":"104","author":"Fadini","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jval.2021.12.016_bib59","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1185\/03007995.2015.1058252","article-title":"Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study","volume":"31","author":"Landstedt-Hallin","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.jval.2021.12.016_bib60","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","article-title":"A\u00a016-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes","volume":"23","author":"Raskin","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jval.2021.12.016_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/dmrr.572","article-title":"A\u00a0randomized multicentre trial of insulin glargine compared with NPH Insulin in people with type 1 diabetes","volume":"21","author":"Home","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib62","first-page":"369","article-title":"Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH Insulin in children and adolescents with type 1 diabetes mellitus","volume":"15","author":"Schober","year":"2002","journal-title":"J\u00a0Pediatr Endocrinol Metab JPEM"},{"issue":"5","key":"10.1016\/j.jval.2021.12.016_bib63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","article-title":"Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of insulin glargine in Type 1 Diabetes","volume":"23","author":"Ratner","year":"2000","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jval.2021.12.016_bib64","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.23.8.1137","article-title":"Basal insulin glargine (HOE 901) versus NPH Insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin glargine (HOE 901) Type 1 Diabetes Investigator Group","volume":"23","author":"Rosenstock","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2021.12.016_bib65","article-title":"Insulin glargine and insulin detemir for type 1 and type 2 diabetes: systematic review of randomised controlled trials","year":"2006","journal-title":"Medical Research Matters Ltd"},{"key":"10.1016\/j.jval.2021.12.016_bib66","article-title":"Long-acting insulin analogues for the treatment of diabetes mellitus: metaanalyses of clinical outcomes \u2013 update of CADTH technology report no. 92. Canadian Agency for Drugs and Technologies in. Health","year":"2008","journal-title":"Health"},{"issue":"4","key":"10.1016\/j.jval.2021.12.016_bib67","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00125-004-1365-z","article-title":"Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH Insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes","volume":"47","author":"Hermansen","year":"2004","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.jval.2021.12.016_bib68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2213-8587(14)70073-7","article-title":"Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blindedendpoint crossover trial","volume":"2","author":"Pedersen-Bjergaard","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jval.2021.12.016_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-12-10","article-title":"A\u00a0prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna Trial): study rationale and design","volume":"12","author":"Kristensen","year":"2012","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jval.2021.12.016_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-8-3","article-title":"Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study","volume":"8","author":"Sharplin","year":"2009","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.jval.2021.12.016_bib71","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.clinthera.2007.08.020","article-title":"Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus","volume":"29","author":"Mullins","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2021.12.016_bib72","series-title":"Insulin Detemir Plus Insulin Aspart Is Associated With Less Risk of Major as Well as Nocturnal Hypoglycaemia Than Insulin Glargine Plus Insulin Aspart at Comparable Levels of Glycaemic Control in Type 1 Diabetes. Diabetologia","author":"Pieber","year":"2005"},{"issue":"5","key":"10.1016\/j.jval.2021.12.016_bib73","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bcp.14188","article-title":"Cost-effectiveness of long-acting insulin analogues vs intermediate\/long-acting human insulin for type 1 diabetes: a population-based cohort followed over 10 years","volume":"86","author":"Lee","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.12.016_bib74","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.12.016_bib75","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1185\/030079904X2006","article-title":"Validation of the CORE Diabetes Model against epidemiological and clinical studies","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.jval.2021.12.016_bib77","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jval.2018.02.002","article-title":"Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge","volume":"21","author":"Palmer","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2021.12.016_bib78","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00134-018-5293-7","article-title":"Industry sponsorship and research outcome: systematic review with meta-analysis","volume":"44","author":"Lundh","year":"2018","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.jval.2021.12.016_bib79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40273-016-0456-2","article-title":"Systematic review of the cost effectiveness of insulin analogues in type 1 and type 2 diabetes mellitus","volume":"35","author":"Shafie","year":"2017","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152200047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152200047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:28:07Z","timestamp":1761096487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152200047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S109830152200047X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.12.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Society for Adolescent Health and Medicine.","name":"copyright","label":"Copyright"}]}}